Taysha Gene Therapies announces proposed public offering of

DALLAS, June 25, 2024 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for serious monogenic diseases of the central nervous system (CNS), today announced that it has launched an underwritten public offering of up to $75 million of common stock and, in lieu of common stock to certain investors who wish, pre-funded warrants to purchase shares of its common stock. All titles will be proposed by Taysha. Taysha also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of its common shares offered in the public offering on the same terms and conditions (including shares under -underlying the pre-funded warrants). The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed or the actual size or terms of the offering.

Jefferies and Goldman Sachs & Co. LLC are acting as joint book-running managers for the offering, and Cantor is also acting as book-running manager for the proposed offering.

A shelf registration statement relating to the securities offered in the public offering described above was filed with the Securities and Exchange Commission (the “SEC”) on October 5, 2021 and declared effective by the SEC on October 14, 2021. October 2021. The offering will be made only by means of a written prospectus and prospectus supplement which form part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022 , or by telephone at (877) 821-7388. , or by email to [email protected]; or Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by e-mail at [email protected] .gs.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities offered, nor shall there be any sale of the securities offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for serious monogenic diseases of the central nervous system. Its lead clinical program, TSHA-102, is being developed for Rett syndrome, a rare neurodevelopmental disorder for which there are no approved disease-modifying treatments that address the root genetic cause of the disease. With a particular focus on the development of transformative medicines, Taysha aims to address serious unmet medical needs and significantly improve the lives of patients and their caregivers. The Company’s management team has proven experience in the development and commercialization of gene therapies. Taysha leverages this experience, its manufacturing process, and a clinically and commercially proven AAV9 capsid with the goal of rapidly translating treatments from bench to bedside.

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “expects”, “intends”, “plans” ”, “plans” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements regarding the potential of TSHA-102 and Taysha’s other product candidates to positively impact quality of life and alter disease outcomes in the patients Taysha seeks to treat, its plans research, development and regulation for its product candidates. , and its planned public offering, including uncertainties relating to market conditions and the consummation of the public offering on the anticipated terms, if any. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Therefore, these forward-looking statements are not guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. The risks relating to Taysha’s business are described in detail in its filings with the SEC, including in Taysha’s Annual Report on Form 10-K for the full fiscal year ended December 31, 2023, which is available at SEC web at www.sec.gov. Additional information will be made available in other documents filed by Taysha from time to time with the SEC. These forward-looking statements speak only as of the date hereof and Taysha undertakes no obligation to update these statements, except as required by law.

Company contact:

Hayleigh Collins
Director, Head of Corporate Communications and Investor Relations
Taysha Genetic Therapies, Inc.
[email protected]

Media Contact:

Carolyn Hawley
Inizio Evoke
[email protected]